Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
VM: Visualization, Writing review and editing
Medication should be discontinued until pancreatitis is ruled out
The Opportunity The pharmacy benefit management (PBM) market valued at $548 billion in 2023 and projected to grow to $898 billion by 2032 is rife with inefficiencies that drive up costs and limit accessibility
TL;DR: Tirzepatide Slows eGFR Decline and Lowers Albuminuria Trials show a slower drop in eGFR and lower albumin leakage signs the kidneys are holding filtration strength over time
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for weight management in adults with obesity or overweight with weight-related comorbidities
US$ 29.25
US$ 28.94
US$ 24.79
US$ 24.84
US$ 28.64
